Business
Health Canada Accepts New Drug Submission for REDUVO(TM) as a Treatment for Patients with Chemotherapy-induced Nausea and Vomiting
Health Canada Accepts New Drug Submission for REDUVO(TM) as a Treatment for Patients with Chemotherapy-induced Nausea and Vomiting.
About this update from Tetra Bio-pharma Inc.
[{"type":"text","content":"This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated May 28, 2021 to its short form base shelf prospectus dated April 1, 2020The Company approaches a significant milestone advancing from a pre-revenue biotech to in revenueOTTAWA, ON / ACCESSWIRE / June 2, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development announced today that Health Canada has accepted its New Drug Submission (NDS) for REDUVO™ and has formally entered the final review phase in the drug review process. If successful, REDUVO™ will be issued a Notice of Compliance (NOC) as well as a Drug Identification Number (DIN) which permits Tetra to market the drug in Canada and indicates the drug's official approval in Canada. REDUVO™ is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV). It is also used to treat weight loss and severe nausea in people living with HIV infection. The active pharmaceutical ingredient in REDUVO™ is dronabinol, also known as THC, a synthetic form of the active natural substance in cannabis."There is a need for alternative therapies for patients experiencing CINV who don't respond well to the conventional drugs used to control nausea and vomiting. Prevention of CINV remains a priority to reduce further illness in patients receiving chemotherapy. Tetra anticipates that REDUVO™ will be publicly and privately reimbursed by provinces and Canadian private healthcare plans," said Chief Executive Officer Dr. Guy Chamberland. "We will continue to work closely with Health Canada as we seek to bring this therapy to patients as soon as possible."About Chemotherapy-induced Nausea and VomitingChemotherapy-induced nausea and vomiting is one of the most common side effects of chemotherapy treatment. Some studies indicate that untreated CINV can affect up to 70% to 80% of all people undergoing chemotherapy1. Patients who poorly manage CINV may have a decreased quality of life.About Tetra Bio-PharmaTetra Bio-Pharma (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed a...